# Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine

Study · id `cardio:ct-nct07704684` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07704684](<https://clinicaltrials.gov/study/NCT07704684>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07704684

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.

## Technical summary

Registry record NCT07704684. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-28 (actual); primary completion 2025-08-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 376 participants (enrolled count; ClinicalTrials.gov record NCT07704684, source copy `cardio:ctgov-nct07704684-2026-07-15`, retrieved 2026-10-26)
- Started: 2023-06-28 (actual) (ClinicalTrials.gov record NCT07704684, source copy `cardio:ctgov-nct07704684-2026-07-15`, retrieved 2026-10-26)
- Primary completion: 2025-08-26 (actual) (ClinicalTrials.gov record NCT07704684, source copy `cardio:ctgov-nct07704684-2026-07-15`, retrieved 2026-10-26)
- Completion: 2025-09-08 (actual) (ClinicalTrials.gov record NCT07704684, source copy `cardio:ctgov-nct07704684-2026-07-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07704684, source copy `cardio:ctgov-nct07704684-2026-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07704684-2026-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine
- Condition: Essential Hypertension
- Intervention (Drug): Experimental: Sacubitril/Allisartan and Amlodipine Group
- Intervention (Drug): Active Comparator: Amlodipine Group
- Lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. (`cardio:org-shenzhen-salubris-pharmaceuticals-co-ltd`)

## Provenance

Content hash: 9fba9bbecb2f6ceee2253eeeb72ac2ad479718163074ffc81f2c8eecaad2e8b5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
